Please assess the completion status of the following clinical trial:

Trial Title: Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Major depressive disorder based on DSM-IV TR criteria~* Age 18-50~* Hamilton Depression Rating scale \>=22~* Signing the informed consent form~* Citalopram be the drug of choice for the patient irrespective of other eligibility criteria~Exclusion Criteria:~* Problems in other Axes~* Pregnancy and lactation~* Serious or life threatening disease~* taking other antidepressant in the recent month or Electroconvulsive shock in the recent two months, and taking other psychotropic agents~* Diabetes controlled with drugs or insulin (patients with only lifestyle interventions will be included), Liver disease, Congestive heart failure Class III and IV~* Metabolic syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Pioglitazone+Citalopram+Chlordiazepoxide (Type: ACTIVE_COMPARATOR): Pioglitazone 15 mg Q12h will be given to the patients in active comparator group for 6 weeks. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.Chlordiazepoxide 10 mg/day for first three weeks
- Placebo+ Citalopram+ Chlordiazepoxide (Type: PLACEBO_COMPARATOR): Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).